A Phase I Study of Intravenous Recombinant Human IL-15(rhIL-15) in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer

Trial Profile

A Phase I Study of Intravenous Recombinant Human IL-15(rhIL-15) in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs Interleukin-15 (Primary)
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2012 Planned number of patients changed from 39 to 18 as reported by ClinicalTrials.gov.
    • 14 Mar 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 25 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top